Current Report Filing (8-k)
August 17 2022 - 6:01AM
Edgar (US Regulatory)
0001624326
false
0001624326
2022-08-16
2022-08-16
0001624326
PAVM:CommonStockParValue0.001PerShareMember
2022-08-16
2022-08-16
0001624326
PAVM:SeriesZWarrantsToPurchaseCommonStockMember
2022-08-16
2022-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 16, 2022
PAVMED
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
001-37685 |
|
47-1214177 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
One
Grand Central Place, Suite 4600, New York, New York |
|
10165 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (212) 949-4319
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, Par Value $0.001 Per Share |
|
PAVM |
|
The
Nasdaq Stock Market LLC |
Series
Z Warrants to Purchase Common Stock |
|
PAVMZ |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. |
Results
of Operations and Financial Condition. |
On
August 16, 2022, PAVmed Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter
ended June 30, 2022 and providing a business update. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated
herein by reference.
Item
7.01. |
Regulation
FD Disclosure. |
The
disclosure set forth under Item 2.02 is incorporated herein by reference.
The
information furnished under Items 2.02 and 7.01, including the exhibit related thereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of
the Company, except as shall be expressly set forth by specific reference in such document.
Item
9.01. |
Financial
Statements and Exhibits. |
Exhibit
No. |
|
Description |
|
|
|
99.1 |
|
Press release. |
|
|
|
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
August 16, 2022
|
PAVMED
INC. |
|
|
|
|
By: |
/s/
Dennis M. McGrath |
|
|
Dennis
M. McGrath |
|
|
President
and Chief Financial Officer |
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Jul 2024 to Aug 2024
PAVmed (NASDAQ:PAVMW)
Historical Stock Chart
From Aug 2023 to Aug 2024